Shire Discontinues Development Of Once-Weekly SHP656 For Hemophilia A
Shire's cash-strapped partner Xenetic, whose technology enabled the long-acting Factor VIII, said on May 22 that SHP656 could not achieve once-weekly dosing in a Phase I/II clinical trial. The market for such a product may be limited anyway given current competition and payer preferences.
You may also be interested in...
Shire's Ornskov On Goals And Accomplishments One Year After Baxalta Merger
Shire's CEO says he sees scientific and technological advances as an opportunity to become the leading rare disease company. Ornskov also talked about the firm's debt-reduction and M&A strategy going forward.
Bioverativ Fills Gap In Pipeline With $400m True North Buy
Bioverativ revealed its first transaction since spinning out from Biogen with the acquisition of True North for $400m plus up to $425m in milestone payments. The deal gives Bioverativ a clinical asset, helping to fill the gap between preclinical programs and commercial products in its R&D pipeline.
Competition Coming For Hemophilia Franchises, But Will Patients And Payers Embrace New Drugs?
Roche's emicizumab, Alnylam's fitusiran and multiple gene therapies may soon steal market share from established clotting factors sold by Shire, Novo Nordisk and others, but safety is a key consideration for physicians and patients.